Gilead Sciences Inc.’s experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study, two months after failing another clinical trial.

The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.

Teva Pharmaceutical Industries Ltd. will stop developing the migraine drug Ajovy for treating cluster headaches after finding the treatment was unlikely to meet the main goal of a late-stage trial.

Eli Lilly announced results from the COAST-X Phase III study of Taltz in non-radiographic axial spondyloarthritis in patients who had no previous disease-modifying anti-rheumatic drug treatment.

The White House is expanding its war on opioid addiction with a $350 million addiction research and treatment initiative.

There has been significant progress in so-called bioprinting – using a type of 3D printing to manufacture biological tissues. But an actual organ had not been accomplished – until now.

Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.

Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.

Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine.